1. © Copyright 2004 Frost & Sullivan. All Rights Reserved. World Generics and Biogenerics Markets Regulatory and Patent Uncertainties Constrain Development of Generic Drugs in Developed Countries Healthcare Group “Generics and biogeneric drugs are emerging as strong contenders to branded medications in virtually all global pharmaceutical markets. With over two dozen patent of blockbuster products expiring over the next few years, U.S. sales of generics are expected to grow by 11.8 percent through 2010.”

2. © Copyright 2004 Frost & Sullivan. All Rights Reserved. Industry Trends  Patent expirations drive market growth in the united states and Europe  Cost cutting initiatives boost generic use worldwide  Biogeneric drug use is poised for strong growth  Regulatory changes stimulate generic product development  Increasing RX-to-OTC switch activity in the U.S., Europe and Canada could cannibalize some generic sales  Regulatory and patent uncertainties constrain development of biogenerics in the u.S. And Europe  Some consumers remain resistant to the use of generics

3. © Copyright 2004 Frost & Sullivan. All Rights Reserved. Key Features Frost & Sullivan Provides:  Detailed insights into recent developments and trends  Drivers, restraints, challenges, and strategic recommendations  Analyst insights on patent expiration in the global generics and biogenerics surgery markets  Market forecasts and opportunity analysis  Growth opportunities and emerging applications  SWOT analysis for companies and technologies

4. © Copyright 2004 Frost & Sullivan. All Rights Reserved. What We Offer  Coverage: Global  Proven methodology encompassing extensive primary and secondary data and research  Focused information and strategies that cover business and technology issues  Credible data and analysis highlighting industry dynamics  Winning strategies to help you create precise business plans

5. © Copyright 2004 Frost & Sullivan. All Rights Reserved. Who Will Benefit? Current Market Participants  Find out how you compare to the competition  Assess current and future drivers and restraints  Determine and exploit new market share opportunities New Entrants  Analyze challenges associated with the industry  Calculate time scales for strategy implementation  Position yourself to capitalize on the market’s unmet needs Investment Community  Analyze long-term strategies of generics and biogenerics companies  Determine which participants will outperform the competition  Assess attractiveness of investing in the generics and biogenerics markets

6. © Copyright 2004 Frost & Sullivan. All Rights Reserved. What’s Included  Drivers, restraints, and trends  Top companies  Challenges faced  Forecasts for generics and biogenerics markets  Patent expirations and opportunities  Global market analysis  Challenges and opportunities in biogenerics markets

7. © Copyright 2004 Frost & Sullivan. All Rights Reserved. Key Market Participants  Alpharma  ANDRX PHARMACEUTICALS, LLC  Apotex, Inc.  Barr laboratories, Inc.  Cipla  Dr. Reddy's  Gedeon Richter  IVAX Corp.  Merck Generics  Mylan Laboratories, Inc.  Pliva  Ranbaxy Laboratories Ltd.  Ratiopharm  Sandoz  Stada  TEVA Pharmaceuticals USA  Watson Pharmaceuticals, Inc.

8. © Copyright 2004 Frost & Sullivan. All Rights Reserved. For More Information  Call toll free: 877 GO FROST (877.463.7876)  Fax toll free: 888.690.3329  E-mail: myfrost@frost.com  Visit: www.frost.com